Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Short-Seller Andrew Left Blasts Michael Saylor′s ′Bitcoin Reactor′ As Q4 Losses Mount:... (Benzinga) +++ STRATEGY INC Aktie +3,32%

COLOPLAST Aktie

 >COLOPLAST Aktienkurs 
65.94 EUR    -8.3%    (Tradegate)
Ask: 65.96 EUR / 550 Stück
Bid: 65.94 EUR / 550 Stück
Tagesumsatz: 6885 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
COLOPLAST Aktie über LYNX handeln
>COLOPLAST Performance
1 Woche: -1,6%
1 Monat: -1,8%
3 Monate: -12,6%
6 Monate: -10,5%
1 Jahr: -33,8%
laufendes Jahr: -1,8%
>COLOPLAST Aktie
Name:  COLOPLAST NAM. B DK 1
Land:  Dänemark
Sektor:  Gesundheit
ISIN/ Wkn:  DK0060448595 / A1KAGC
Symbol/ Ticker:  CBHD (Frankfurt)
Kürzel:  FRA:CBHD, ETR:CBHD, CBHD:GR
Index:  -
Webseite:  https://www.coloplast.com..
Profil:  Coloplast A/S operates as a major player in the he..
>Volltext..
Marktkapitalisierung:  16096.89 Mio. EUR
Unternehmenswert:  18989.37 Mio. EUR
Umsatz:  3699.75 Mio. EUR
EBITDA:  1198.83 Mio. EUR
Nettogewinn:  482.61 Mio. EUR
Gewinn je Aktie:  2.14 EUR
Schulden:  3004.9 Mio. EUR
Liquide Mittel:  125.7 Mio. EUR
Operativer Cashflow:  882 Mio. EUR
Bargeldquote:  0.15
Umsatzwachstum:  2.81%
Gewinnwachstum:  -28.25%
Dividende je Aktie:  3.08 EUR
Dividendenrendite:  4.29%
Dividendenschätzung:  4.29%
Div. Historie:  05.12.25 - 2.4075€
08.05.25 - 0.6691€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  COLOPLAST
Letzte Datenerhebung:  06.02.26
>COLOPLAST Kennzahlen
Aktien/ Unternehmen:
Aktien: 207.37 Mio. St.
Frei handelbar: 68.87%
Leerverk. Aktien: -
Rückkaufquote: -0.02%
Mitarbeiter: 16907
Umsatz/Mitarb.: 0.22 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: 23.56%
Bewertung:
KGV: 32.79
KGV lG: 20.5
KUV: 4.32
KBV: 7.4
PEG-Ratio: -
EV/EBITDA: 15.84
Rentabilität:
Bruttomarge: 67.97%
Gewinnmarge: 13.04%
Operative Marge: 27.19%
Managementeffizenz:
Gesamtkaprendite: 7.54%
Eigenkaprendite: 21.35%
 >COLOPLAST Anleihen 
>COLOPLAST Peer Group
Gesundheit
 
06.02.26 - 09:30
Coloplast tumbles after soft Q1 hit by reimbursement disruption at Kerecis (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.02.26 - 09:06
Coloplast A/S Reports Advance In Q1 Profit (AFX)
 
BRUSSELS (dpa-AFX) - Coloplast A/S (COLO-B.CO) reported earnings for its first quarter that Increases, from the same period last yearThe company's earnings totaled DKK1.397 billion, or DKK6.20 per......
06.02.26 - 07:33
Coloplast A/S - Interim Financial Report, Q1 2025/26 (GlobeNewswire EN)
 
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025...
27.01.26 - 07:48
3Shape appoints Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy (Cision)
 
[image] Copenhagen, Denmark, January 27, 2026 – 3Shape today announced the appointment of Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy, effective 9 March. Rasmus will step into the Senior Leadership Team and will report directly to CEO Jacob Paulsen. Rasmus joins 3Shape from Coloplast, where he spent more than 20 years in senior leadership roles spanning strategy, product management, marketing, and global business leadership. Most recently, he served as Vice President, Group Development & Strategy, with responsibility for corporate strategy, M&A, and post-...
26.01.26 - 13:06
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conference call on 6 Feb 2026 at 11.00am CET (GlobeNewswire EN)
 
Friday, 6 February 2026 at 11:00-12:00am CETIn connection with the publication of Coloplast's interim financial results for Q1 2025/26, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast's website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the event....
23.01.26 - 12:03
Coloplast Finance B.V. - Decisions at the Annual General Meeting (GlobeNewswire EN)
 
On 23 January 2026, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2024/25. In addition, EY Accountants B.V. was appointed as auditor for Coloplast Finance B.V....
18.12.25 - 15:03
Coloplast announces changes to Executive Leadership Team (GlobeNewswire EN)
 
Today, Coloplast is announcing changes to the company's Executive Leadership Team (ELT). The changes relate to the company's Interventional Urology business as well as the global People & Culture function....
04.12.25 - 17:54
Coloplast A/S - Decisions at the Annual General Meeting 2025 (GlobeNewswire EN)
 
Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:...
03.12.25 - 23:54
XFRA: DIVIDEND/INTEREST INFORMATION - 05.12.2025 - DK0060448595 (XETRA)
 
Das Instrument CBHD DK0060448595 COLOPLAST NAM. B DK 1 EQUITY wird cum Dividende/Zinsen gehandelt am 04.12.2025 und ex Dividende/Zinsen am 05.12.2025 The instrument CBHD DK0060448595 COLOPLAST NAM. B DK 1 EQUITY has its pre-dividend/interest day on 04.12.2025 and its ex-dividend/interest day on 05.12.2025...
11.11.25 - 10:15
Coloplast A/S - Notice of Annual General Meeting 2025 (GlobeNewswire EN)
 
Notice of Annual General Meeting 2025...
04.11.25 - 14:27
Coloplast Finance B.V. - Annual Report, 2024/25 (GlobeNewswire EN)
 
Hereby please find the Annual Report 2024/25 for the group of Coloplast A/S....
04.11.25 - 10:57
Coloplast climbs on Q4 margin beat, in-line organic sales growth (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
04.11.25 - 08:54
Coloplast Q4 Profit Falls; Proposes DKK 18 Dividend (AFX)
 
BRUSSELS (dpa-AFX) - Coloplast A/S (COLO-B.CO), a medical devices manufacturer, reported weaker results for the fourth quarter , as special items and higher costs weighed on profitability despite ......
04.11.25 - 07:36
Coloplast A/S - Full-Year Financial Results 2024/25 (GlobeNewswire EN)
 
2024/25Full year financial results...
04.11.25 - 07:36
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 (GlobeNewswire EN)
 
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25...
30.09.25 - 14:42
Coloplast A/S - Financial Calendar 2025-26 (GlobeNewswire EN)
 
Please see enclosed pdf....
02.09.25 - 12:03
Coloplast shares gain on updated mid-term guidance (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.09.25 - 08:09
Coloplast A/S - Coloplast presents new 5-year strategy, Impact4 (GlobeNewswire EN)
 
The new 5-year strategy, Impact4, will be presented today at the company's Capital Markets Day 2025...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer immer sich zu mir bekennt vor den Menschen, zu dem werde auch ich mich bekennen vor meinem Vater in den Himmeln. - Neues Testament: Evangelium nach Matthäus
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!